Navigation Links
Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23

vantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.Orexigen.com.

Forward Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. For example, statements regarding the potential efficacy of Contrave(TM) may be forward looking statements. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Orexigen's business, including, without limitation: the results of this Phase IIb clinical trial and earlier clinical trials may not be predictive of future results; Orexigen's pending clinical trials may not proceed in the timeframes or in the manner Orexigen expects or at all; unexpected findings relating to Contrave(TM) or Empatic(TM) that could delay or prevent regulatory filings, approval or commercialization, or that could result in recalls or product liability claims; Orexigen and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in Orexigen's public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by t
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:7/1/2015)... KONG and FT LAUDERDALE, Florida ... Inc. ("OrbusNeich"), a designer, developer, manufacturer and marketer of innovative ... that on May 13, 2015, it prevailed in a final ... European Patent EP 1 341 482 - STENT HAVING HELICAL ... of review in the EPO and has been upheld as ...
(Date:7/1/2015)... , July 1, 2015  Imprimis Pharmaceuticals, Inc. ... on the development and commercialization of proprietary compounded ... ring The Nasdaq stock market closing bell on ... growing success of its Go Dropless™ campaign since ... cataract procedures are performed annually in the U.S. ...
(Date:7/1/2015)...  LabStyle Innovations Corp. (DRIO), developer of the ... of Todd Durniak as Senior Vice President and General ... over 20 years of medical device commercial and ... and General Manager of Neighborhood Diabetes, a division ... durable medical equipment (DME) and pharmacy channels with ...
Breaking Medicine Technology:OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 2LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 3LabStyle Innovations Appoints Senior VP & General Manager in U.S. for the Dario Diabetes Management Solution 4
... SILVER SPRING, Md., Oct. 7, 2011 The U.S. ... simvastatin), a fixed-dose combination (FDC) prescription medication that contains ... in adults who need both sitagliptin and simvastatin. ... million people in the United States have type 2 ...
... Oct. 7, 2011 ProteinSimple today announced plans ... service support for its biologics products in Europe, ... are included in this expanded support structure:  iCE ... systems. The biologics market segment is ...
Cached Medicine Technology:FDA Approves Combination Therapy Juvisync 2FDA Approves Combination Therapy Juvisync 3ProteinSimple to Offer Direct Sales, Service and Support for Biologics Products in Europe 2
(Date:7/1/2015)... (Colorado Springs, Colorado) , ... - (PRWEB) July 01, 2015 , ... ... be hosting a nationwide virtual 5K on August 15-16th (MSG Keys’ birthday) in memory ... Bradley Keys, a highly decorated soldier and recipient of the Bronze Star Medal, died ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... said lead author Lisa Stolzenberg, a Professor in FIU’s School of International and ... 12 to 17 years who participated in the National Survey on Drug Use ...
(Date:7/1/2015)... ... 2015 , ... Scoliosis is a disorder in which the normally straight vertical line of the ... 3 percent of the population, or an estimated 6 to 9 million people. While it ... ages of 10 and 15. Most types of scoliosis are more common in girls than ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... premium delicatessen products, is helping families get ready for Independence Day celebrations with ... sliders, these easy and versatile options are perfect for any summertime get together. ...
(Date:7/1/2015)... Mesa, Arizona (PRWEB) , ... July 01, 2015 , ... ... recently opened a new office in the greater Phoenix area – their Mesa, ... the move to senior care with their purchase of the rights to the area ...
Breaking Medicine News(10 mins):Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:Boar’s Head Helps Craft a Delicious Independence Day 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 3Health News:Amada Senior Care Expands to Greater Phoenix Area 2
... 150 cases of measles have been reported in the ... similar outbreaks in Europe, a sign the disease is ... deadly virus is the result of unfounded fears about ... have turned some parents against childhood vaccination, says Gregory ...
... , TUESDAY, Aug. 30 (HealthDay News) -- The extent ... by inserting a balloon pump into the aorta -- the ... surgery to clear clogged blood vessels known as angioplasty, a ... pump (IABP), is designed to increase blood supply to the ...
... Aug. 30 (HealthDay News) -- Intense competition, not violence, ... fuels aggression, according to a small new study. ... video games such as "Fuel," "Mortal Kombat" and "Left ... competitiveness and violence. The participants, levels of aggression were ...
... Results of the independently-funded Bern-Rotterdam cohort study provide ... and very late stent thrombosis. The reduction in ... stent (EES) was compared with early generation drug-eluting ... near elimination of stent thrombosis observed between one ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... resisting temptation are more likely than patient preschoolers to ... suggests. "What we,re seeing is that there are ... delayers," lead study author B.J. Casey, a cognitive neuroscientist ...
... 30 (HealthDay News) -- ,Having a secure attachment with their ... situations, a new study finds. It included 84 infants ... assessed within a month of birth and was based on ... undressed and hearing a bell ringing. About one third of ...
Cached Medicine News:Health News:Mayo Clinic physician: Mistaken fear of measles shot has 'devastating' effect 2Health News:Heart Attack Damage Not Reduced by Adding Balloon Pump to Angioplasty 2Health News:An 'important' reduction in risk of stent thrombosis with everolimus-eluting stent 2Health News:'Gimme' Kids Often Grow Into 'Gimme' Adults 2Health News:'Gimme' Kids Often Grow Into 'Gimme' Adults 3
Inquire...
Inquire...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: